New drug targets rare gene fault in advanced cancers

NCT ID NCT07128303

Recruiting now Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This early-phase study tests a new drug called GS-5319 in adults with advanced solid tumors that lack a gene called MTAP. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. About 178 participants whose cancer has not responded to standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Asan Medical Center
RECRUITING

Seoul, 05505, South Korea
Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START - Centro Oncológico Clara Campal
RECRUITING

Madrid, 28050, Spain
START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit
RECRUITING

Madrid, 28040, Spain
START San Antonio
RECRUITING

San Antonio, Texas, 78229, United States
Samsung Medical Center
RECRUITING

Seoul, 06351, South Korea
Vall d'Hebron Institute of Oncology (VHIO)
RECRUITING

Barcelona, 08035, Spain

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR